BioCentury on BioBusiness,
Politics and Policy
HHS: Give Medicare more power to control drug costs; Congress unlikely to do so
Monday, September 12, 2011
After comparing the costs of Genentech
Inc.'s Avastin bevacizumab and Lucentis ranibizumab to treat wet AMD,
the HHS inspector general has called for giving Medicare more power to control
drug spending. It is the latest in a long history of calls for CMS to deny
coverage of one drug in favor of a less expensive alternative. But given its
current makeup, Congress looks unlikely to make the legal change required for
the agency to implement such a policy.
Last week's Office of Inspector
General (OIG) report documented the difference in acquisition costs for
Lucentis and Avastin for wet age-related macular degeneration. The report said
using Avastin instead of Lucentis for two years during 2008 and 2009 would have
saved Medicare Part B $1.1 billion, while beneficiaries would have saved $275
million in co-payments.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2015 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]